Based on these findings, pembrolizumab was approved in the United States for previously treated patients with advanced gastric cancer expressing a combined positive score (CPS) ≥ 1% on the programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) test10,11. Here, CD274 is linked to gastric cancer.